American association for cancer research-101st annual meeting-investigating new therapeutic candidates: part 2.
VL Mason - Idrugs: the Investigational Drugs Journal, 2010 - europepmc.org
VL Mason
Idrugs: the Investigational Drugs Journal, 2010•europepmc.orgThe 101st Annual Meeting of the American Association of Cancer Research, held in
Washington, DC, included topics covering new therapeutic developments in the field of
cancer research. This conference report highlights selected presentations on preclinical
data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual
inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1
inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F …
Washington, DC, included topics covering new therapeutic developments in the field of
cancer research. This conference report highlights selected presentations on preclinical
data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual
inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1
inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F …
The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.
europepmc.org